9AA treatment of renal carcinoma cells and HTLV-1 infected T-cells demonstrated NF-κB inhibition and p53 activation, with NF-κB inhibition being upstream of p53 activation [41,45,46]. The gene discussed is TP53; the disease is renal carcinoma.